secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001213900-25-031590
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio partners with CGT Catapult to scale CORDStrom manufacturing for commercial readiness
--------------------------------------------------------------------------------

- Partnership with Cell and Gene Therapy Catapult aims to establish large-scale commercial manufacturing for cell therapy platforms.
- Initial focus on scaling CORDStrom for RDEB; Phase 2 trial showed reduced pain/itch and improved skin integrity.
- INmune estimates 4,000 children with intermediate-to-severe RDEB in US/UK/EU could benefit from CORDStrom.
- Following CORDStrom, INmune plans to transition INKmune production to same facility for solid tumor trials.
- Manufacturing will leverage CGT Catapult's Stevenage Innovation Centre and existing Royal Free Hospital base.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025031590/0001213900-25-031590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025031590/ea0238180-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-031590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer